A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of repeat doses of solabegron and oxybutynin when taken alone or together

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Mandelic Acids; Oxybutynin; Solabegron

Criteria

Inclusion Criteria:

• Healthy adult males & females ages 18-65;

• Body weight >50kg; BMI between 19-32;

• Signed and dated informed consent; QTc Interval <450 msec;

Exclusion Criteria:

• Resting blood pressure >140/90 mmHg or HR >100 at screening;

• History of drug allergy or other allergy which, in the opinion of the PI, contraindicates their participation;

• Positive urine drug, alcohol or serum pregnancy test at screening and prior to dosing;

• Positive HIV, Hepatitis B, C at screening; use of medications (except acetaminophen)or vitamins or herbal supplements within 7 days or 5 half lives prior to dosing and during study;

• history of urinary retention, gastric retention, and other sever gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma or who are at risk for these conditions;

• history of chronic constipation and/or regular laxative use; donation of more than 500mL of blood within 56 days prior to dosing;

• clinically relevant abnormality identified during screening process or any medical condition or circumstance making the subject unsuitable for participation based on the Investigators assessment